Friday, December 15, 2017
 
 
Company News: Page (1) of 1 - 12/05/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Pascal Announces the Appointment of a New Director, Dr. Graeme I. Bell

(December 05, 2017)

VANCOUVER, B.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSX VENTURE:PAS), a biotechnology company that specializes in cancer drug discovery and development, today announced the appointment of Dr. Graeme I. Bell to its Board of Directors.

Dr. Bell received his BSc and MSc degrees from the University of Calgary and his PhD from the University of California, San Francisco. He is currently the Kovler Family Distinguished Service Professor in Medicine, and Human Genetics at the University of Chicago. Dr. Bell is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. For his pioneering work on the genetics of diabetes, he was awarded the 2013 Banting Medal for Scientific Achievement Award, the highest scientific honor from the American Diabetes Association. This prize is awarded annually in memory of the Canadian medical scientist Sir Frederick Banting, Nobel laureate who was one of the key investigators that discovered insulin.

“Dr. Bell is an exceptional medical scientist, and we are very pleased to have him join our Board,” said Dr. Patrick Gray, CEO of Pascal. “In addition to his distinguished and decorated career in medicine, Dr. Bell’s work has been the focus of entrepreneurial biotech startups. His significant insights will be invaluable as we develop novel therapeutics for cancer and advance these through clinical development.”

Dr. Bell has been honored with numerous additional awards recognizing his seminal contributions to the understanding of diabetes and metabolic disease. He gained recognition early in his career for the cloning of the human insulin gene, a landmark achievement that paved the way for the production of recombinant insulin. Demonstrating his entrepreneurial spirit, he became a founding scientist at Chiron, a leading biotechnology company that was later acquired by Novartis.  He has also been a founder and advisor for other biotech startups.

This appointment is subject to the TSXV approval.

On Behalf of the Board of Directors

Patrick W. Gray, President & CEO

Company Contact: Dr. Patrick Gray


Tel: 1-206-650-6765

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

 


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines